Authors
Loading...
Analysis reveals a significant decline in ITP mortality post-eltrombopag and romiplostim approval, highlighting drug impact.
Eli Zolotov (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: